Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer (vol 9, 73, 2023)

被引：0
|
作者：
Fabi, Alessandra
Carbognin, Luisa
Botticelli, Andrea
Paris, Ida
Fuso, Paola
Savastano, Maria Cristina
La Verde, Nicla
Strina, Carla
Pedersini, Rebecca
Guarino, Stefania
Curigliano, Giuseppe
Criscitiello, Carmen
Raffaele, Mimma
Beano, Alessandra
Franco, Antonio
Valerio, Maria Rosaria
Verderame, Francesco
Fontana, Andrea
Haspinger, Eva Regina
Caldara, Alessia
Di Leone, Alba
Tortora, Giampaolo
Giannarelli, Diana
Scambia, Giovanni
机构：
[1] Fondazione Policlinico Universitario A. Gemelli IRCCS,Precision Medicine Unit in Senology
[2] Fondazione Policlinico Universitario A. Gemelli IRCCS,Division of Gynecology Oncology, Department of Woman and Child Health and Public Health
[3] University of Rome,Medical Oncology Unit, La Sapienza
[4] Medical Oncology Unit,Department of Oncology and Hemato
[5] A.O.U. San Giovanni di Dio e Ruggi D’Aragona,Oncology
[6] Medical Oncology Unit,Department of Medical Oncology1
[7] ASST Fatebenefratelli Sacco PO Luigi Sacco - Polo Universitario,Breast Unit, Department of Women, Children and Public Health Sciences
[8] Medical Oncology Unit Azienda Socio-Sanitaria Territoriale Cremona,Medical Oncology, Department of Translational Medicine and Surgery
[9] Medical Oncology Unit ASST Spedali Civili,Epidemiology and Biostatistics Facility
[10] Medical Oncology Unit Santa Maria della Misericordia Hospital,undefined
[11] University of Milan,undefined
[12] Division of Early Drug Development,undefined
[13] European Institute of Oncology,undefined
[14] IRCCS,undefined
[15] Presidio Cassia Sant’andrea,undefined
[16] Dipartimento Oncologico,undefined
[17] Asl Roma1,undefined
[18] Città della Salute e della Scienza Hospital,undefined
[19] Fondazione Policlinico Universitario Agostino Gemelli IRCCS,undefined
[20] Medical Oncology,undefined
[21] Policlinico Universitario P. Giaccone,undefined
[22] Medical Oncology,undefined
[23] AO Riuniti Villa Sofia,undefined
[24] Cervello,undefined
[25] Medical Oncology Unit 2,undefined
[26] Azienda Ospedaliero-Universitaria Pisana,undefined
[27] Azienda Sanitaria dell’Alto Adige – Ospedale di Merano,undefined
[28] Santa Chiara Hospital,undefined
[29] Medical Oncology,undefined
[30] Fondazione Policlinico Universitario A. Gemelli IRCCS,undefined
[31] Università Cattolica del Sacro Cuore,undefined
[32] Fondazione Policlinico Universitario A. Gemelli IRCCS,undefined
[33] Università Cattolica del Sacro Cuore,undefined
来源：
NPJ BREAST CANCER | 2024年 / 10卷 / 01期
关键词：
D O I：
10.1038/s41523-024-00619-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [41] KEYNOTE-086 cohort B: Pembrolizumab monotherapy for PD-L1-positive, previously untreated, metastatic triple-negative breast cancer (mTNBC)
    Adams, Sylvia
    Loi, Sherene
    Toppmeyer, Deborah L.
    Cescon, David W.
    De laurentiis, Michele
    Nanda, Rita
    Winer, Eric P.
    Mukai, Hirofumai
    Tamura, Kenji
    Armstrong, Anne C.
    Liu, Minetta C.
    Iwata, Hiroji
    Ryvo, Larisa
    Wimberger, Pauline
    Rugo, Hope S.
    Tan, Antoinette
    D'Aquanno, Christine
    Ding, Yu
    Karantza, Vassiliki
    Schmid, Peter
    CANCER RESEARCH, 2018, 78 (04)
  • [42] nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial
    Yardley, D. A.
    Coleman, R.
    Conte, P.
    Cortes, J.
    Brufsky, A.
    Shtivelband, M.
    Young, R.
    Bengala, C.
    Ali, H.
    Eakel, J.
    Schneeweiss, A.
    de la Cruz-Merino, L.
    Wilks, S.
    O'Shaughnessy, J.
    Gluck, S.
    Li, H.
    Miller, J.
    Barton, D.
    Harbeck, N.
    ANNALS OF ONCOLOGY, 2018, 29 (08) : 1763 - 1770
  • [43] A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer
    Gamucci, Teresa
    Mentuccia, Lucia
    Natoli, Clara
    Sperduti, Isabella
    Cassano, Alessandra
    Michelotti, Andrea
    Di Lauro, Luigi
    Sergi, Domenico
    Fabi, Alessandra
    Sarobba, Maria G.
    Marchetti, Paolo
    Barba, Maddalena
    Magnolfi, Emanuela
    Maugeri-Sacca, Marcello
    Rossi, Ernesto
    Sini, Valentina
    Grassadonia, Antonino
    Pellegrini, Domenica
    Astone, Antonino
    Nistico, Cecilia
    Angelini, Franco
    Vaccaro, Angela
    Pellegrino, Arianna
    De Angelis, Claudia
    Palleschi, Michela
    Moscetti, Luca
    Bertolini, Ilaria
    Buglioni, Simonetta
    Giordano, Antonio
    Pizzuti, Laura
    Vici, Patrizia
    JOURNAL OF CELLULAR PHYSIOLOGY, 2017, 232 (06) : 1571 - 1578
  • [44] Strong and Sustained Response to Treatment with Carboplatin plus Nab-Paclitaxel in a Patient with Metastatic, Triple-Negative, BRCA1-Positive Breast Cancer
    Shakir, Abdur R.
    CASE REPORTS IN ONCOLOGY, 2014, 7 (01): : 252 - 259
  • [45] Carboplatin-Cyclophosphamide or Paclitaxel without or with Bevacizumab as First-Line Treatment for Metastatic Triple-Negative Breast Cancer (BOOG 2013-01)
    Van Rossum, Annelot G. J.
    Mandjes, Ingrid A. M.
    Van Werkhoven, Erik
    Van Tinteren, Harm
    Van Leeuwen-Stok, A. Elise
    Nederlof, Petra
    Portielje, Johanna E. A.
    Van Alphen, Robbert J.
    Platte, Els
    Van den Broek, Daan
    Huitema, Alwin
    Kok, Marleen
    Linn, Sabine C.
    Oosterkamp, Hendrika M.
    BREAST CARE, 2021, 16 (06) : 598 - 606
  • [46] Real-World Survival and Treatment Regimens Across First- to Third-Line Treatment for Advanced Triple-Negative Breast Cancer
    Celik, Alan
    Berg, Tobias
    Jensen, Maj-Britt
    Jakobsen, Erik
    Nielsen, Hanne Melgaard
    Kumler, Iben
    Glavicic, Vesna
    Jensen, Jeanette Dupont
    Knoop, Ann
    BREAST CANCER-BASIC AND CLINICAL RESEARCH, 2023, 17
  • [47] Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study
    Adams, S.
    Loi, S.
    Toppmeyer, D.
    Cescon, D. W.
    De Laurentiis, M.
    Nanda, R.
    Winer, E. P.
    Mukai, H.
    Tamura, K.
    Armstrong, A.
    Liu, M. C.
    Iwata, H.
    Ryvo, L.
    Wimberger, P.
    Rugo, H. S.
    Tan, A. R.
    Jia, L.
    Ding, Y.
    Karantza, V.
    Schmid, P.
    ANNALS OF ONCOLOGY, 2019, 30 (03) : 405 - 411
  • [48] tnAcity: A phase 2/3 randomized study of weekly nab-paclitaxel in combination with either gemcitabine or carboplatin vs gemcitabine/carboplatin as first-line treatment for triple-negative metastatic breast cancer
    Yardley, D. A.
    Brufsky, A.
    Conte, P.
    Cortes, J.
    Glueck, S.
    Nabholtz, J-Ma
    O'Shaughnessy, J.
    Li, L.
    Barton, D.
    Fandi, A.
    Harbeck, N.
    CANCER RESEARCH, 2013, 73
  • [49] Genomic profiling and clinical outcomes with first-line atezolizumab and nab-paclitaxel in triple-negative breast cancer: An exploratory analysis from the phase 3 IMpassion130 trial
    Emens, Leisha
    Molinero, Luciana
    Adams, Sylvia
    Rugo, Hope S.
    Schneeweiss, Andreas
    Dieras, Veronique
    Iwata, Hiroji
    Barrios, Carlos
    Winer, Eric P.
    Chang, Ching-Wei
    Chui, Stephen Y.
    Schmid, Peter
    Loi, Sherene
    CANCER RESEARCH, 2021, 81 (04)
  • [50] COLET: A multistage, phase 2 study evaluating the safety and efficacy of cobimetinib in combination with paclitaxel as first-line treatment for patients with metastatic triple-negative breast cancer
    Kim, S-B
    Miles, D.
    Rhee, J.
    Yan, Y.
    Hsu, J.
    Brufsky, A.
    CANCER RESEARCH, 2016, 76
12345